Safety study of Jivi for hemophilia A in Korea
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is checking the safety of Jivi (a Factor VIII medicine) when used in normal medical care for people with hemophilia A in Korea. It is for anyone 12 or older who has used Factor VIII before or is starting Jivi as part of their regular treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have hemophilia A (Factor VIII deficiency).
- You have been treated with Factor VIII before, or you are already taking or planning to start the medicine Jivi (damoctocog alfa pegol).
- You are not taking part in any other research study.
- You do not have any other bleeding disorder besides hemophilia A.
- You are not allergic to any part of Jivi (like mouse or hamster proteins).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study looks at how safe and effective Octocog alfa (a Factor VIII medicine) is for treating sudden bleeds in adults with severe hemophilia A in India. It is for people who already have experience with Factor VIII products and are not on regular preventive treatment.
This Phase 1 study tests a gene therapy designed to help the body make factor VIII (FVIII), which is missing in hemophilia A. It may help reduce bleeding and the need for FVIII infusions, but it is an early-safety trial.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.